Ibudilast Granted Fast Track Designation for Methamphetamine Dependence

Share this article:

MediciNova announced that the FDA has granted Fast Track designation for Ibudilast (MN-166) for the treatment of methamphetamine dependence. MN-166 is a first-in-class, orally bioavailable, small molecule phosphodiesterase (PDE) -4 and -10 inhibitor and a macrophage migration inhibitory factor (MIF) inhibitor that suppresses pro-inflammatory cytokines including IL-1SS, TNF-a, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10 and neurotrophic factors. It has also been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its therapeutic action.

Studies for clinical development of MN-166 are currently ongoing in both methamphetamine addiction and opioid addiction.

For more information call (858) 373-1500 or visit www.medicinova.com
Share this article:

Related Resources

close

Next Article in Drugs in the Pipeline